Literature DB >> 23837468

'I cry every day': experiences of patients co-infected with HIV and multidrug-resistant tuberculosis.

Petros Isaakidis1, Sheela Rangan2, Anagha Pradhan3, Joanna Ladomirska1, Tony Reid4, Karina Kielmann5.   

Abstract

OBJECTIVES: To understand patients' challenges in adhering to treatment for MDR-TB/HIV co-infection within the context of their life circumstances and access to care and support.
METHODS: Qualitative study using in-depth interviews with 12 HIV/MDR-TB co-infected patients followed in a Médecins Sans Frontières (MSF) clinic in Mumbai, India, five lay caregivers and ten health professionals. The data were thematically analysed along three dimensions of patients' experience of being and staying on treatment: physiological, psycho-social and structural.
RESULTS: By the time patients and their families initiate treatment for co-infection, their financial and emotional resources were often depleted. Side effects of the drugs were reported to be severe and debilitating, and patients expressed the burden of care and stigma on the social and financial viability of the household. Family caregivers were crucial to maintaining the mental and physical health of patients, but reported high levels of fatigue and stress. Médecins Sans Frontières providers recognised that the barriers to patient adherence were fundamentally social, rather than medical, yet were limited in their ability to support patients and their families.
CONCLUSIONS: The treatment of MDR-TB among HIV-infected patients on antiretroviral therapy is hugely demanding for patients, caregivers and families. Current treatment regimens and case-holding strategies are resource intensive and require high levels of support from family and lay caregivers to encourage patient adherence and retention in care.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  HIV; India; adherence; co-infection; multidrug-resistant tuberculosis; qualitative

Mesh:

Substances:

Year:  2013        PMID: 23837468     DOI: 10.1111/tmi.12146

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  35 in total

1.  Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.

Authors:  A M Kelly; B Smith; Z Luo; B Given; T Wehrwein; I Master; J E Farley
Journal:  Int J Tuberc Lung Dis       Date:  2016-04       Impact factor: 2.373

2.  TB and TB-HIV care for adolescents and young adults.

Authors:  L A Enane; J Eby; T Arscott-Mills; S Argabright; C Caiphus; B Kgwaadira; A P Steenhoff; E D Lowenthal
Journal:  Int J Tuberc Lung Dis       Date:  2020-02-01       Impact factor: 2.373

3.  Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial.

Authors:  Anthony J Garcia-Prats; Penelope C Rose; Heather R Draper; James A Seddon; Jennifer Norman; Helen M McIlleron; Anneke C Hesseling; H Simon Schaaf
Journal:  Pediatr Infect Dis J       Date:  2018-12       Impact factor: 2.129

4.  Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon - a qualitative study exploring the experiences and perceptions of patients and healthcare professionals.

Authors:  Thomas W McNally; Gilles de Wildt; Graciela Meza; Connie M D Wiskin
Journal:  BMC Health Serv Res       Date:  2019-08-22       Impact factor: 2.655

5.  Disadvantage and the Experience of Treatment for Multidrug-Resistant Tuberculosis (MDR-TB).

Authors:  Holly A Taylor; David W Dowdy; Alexandra R Searle; Andrea L Stennett; Vadim Dukhanin; Alice A Zwerling; Maria W Merritt
Journal:  SSM Qual Res Health       Date:  2022-01-28

6.  Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.

Authors:  R Court; M T Chirehwa; L Wiesner; N de Vries; J Harding; T Gumbo; G Maartens; H McIlleron
Journal:  Int J Tuberc Lung Dis       Date:  2019-10-01       Impact factor: 2.373

7.  Loss-To-Follow-Up on Multidrug Resistant Tuberculosis Treatment in Gujarat, India: The WHEN and WHO of It.

Authors:  Kalpita S Shringarpure; Petros Isaakidis; Karuna D Sagili; R K Baxi
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

8.  Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India.

Authors:  Petros Isaakidis; Mrinalini Das; Ajay M V Kumar; Christopher Peskett; Minni Khetarpal; Arun Bamne; Balkrishna Adsul; Mamta Manglani; Kuldeep Singh Sachdeva; Malik Parmar; Avinash Kanchar; B B Rewari; Alaka Deshpande; Camilla Rodrigues; Anjali Shetty; Lorraine Rebello; Peter Saranchuk
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

9.  Multidrug-resistant tuberculosis patients' views of interventions to reduce treatment loss to follow-up.

Authors:  T Tupasi; A M C G Garfin; J M Mangan; R Orillaza-Chi; L C Naval; G I Balane; R Basilio; A Golubkov; E S Joson; W-J Lew; V Lofranco; M Mantala; S Pancho; J N Sarol; A Blumberg; D Burt; E V Kurbatova
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

10.  HIV, multidrug-resistant TB and depressive symptoms: when three conditions collide.

Authors:  Mrinalini Das; Petros Isaakidis; Rafael Van den Bergh; Ajay M V Kumar; Sharath Burugina Nagaraja; Asmaa Valikayath; Santosh Jha; Bindoo Jadhav; Joanna Ladomirska
Journal:  Glob Health Action       Date:  2014-09-09       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.